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Abstract 
The high prevalence and rapid spread of human immunodeficiency virus (HIV) 
across sub-Saharan Africa is a public health problem of unprecedented scale. Acquired 
lmmtmodeficiency Syndrome (AIDS) related morbidity and mortality predominantly 
affects young adults in the prime of their working and reproductive years. As a result, the 
HIV I AIDS pandemic in sub-Saharan Africa has had a detrimental impact on societal and 
family structures as well as economic growth and development. In order to counter these 
effects, an initiative introduced in 2003 by the World Health Organization sought to make 
highly active antiretroviral therapy (HAART) available to poor populations living in 
underdeveloped countries. 
Patients must remain on HAART for life if the treatment is to be effective. One 
of the problems faced with implementing antiretroviral therapy (ART) in resource-limited 
settings is that care is often based on hematologic parameters, necessitating a reliable and 
modem laboratory infrastructure. The WHO has determined that a lack oflaboratory 
infrastructure should not preclude the implementation of ART programs and, in the 
absence of such infrastructure, has made available alternate methodologies on which to 
base care. 
Anemia is a common condition found in HIV positive individuals, and certain 
antiretroviral drugs may cause or exacerbate this condition. Use of a low-tech 
Hemoglobin Color Scale to estimate anemia is suggested in areas, such as developing 
cotmtries in Africa, where automated hematology equipment is unavailable. However, 
few studies have been done to assess the appropriateness of its use in antiretroviral 
programs. For this reason, further research should be undertaken to assess the 
performance ofthe Hemoglobin Color Scale. Given the uncertainty of the effectiveness 
of the Hemoglobin Color Scale, alternative diagnostic methods should also be 
investigated. 
This paper reviews what it known about the performance of the Hemoglobin 
Color Scale. The primary benefits of this method of anemia detection include low cost 
and low infrastructure requirements. The main limitation to this method is that few 
studies have been published to assess its accuracy and no studies have been published to 
directly assess the impact that use has on clinical care. Diagnostic tests may perform 
differently depending on the patient population and prevalence of the disease of interest. 
These factors should be taken into account when assessing the performance of a 
diagnostic test. For this reason, studies that evaluate the Hemoglobin Color Scale should 
provide information not only about test performance, but also about background 
parameters and clinical interventions. 
This paper provides suggestions for future study into low-tech methods of anemia 
diagnosis and describes how some of these considerations may be addressed. 
Additionally, preliminary evidence is presented that supports the study of a centrifuged 
hematocrit as an alternative method of anemia diagnosis. An example is given of 
prospective study design that could be carried out in an antiretroviral therapy program in 
Lusaka, Zambia to assess the performance of both the hemoglobin color scale and a 
manual hematocrit in a clinical setting. 
The goal of identifying reliable low-tech diagnostics is to allow for easier 
expansion of public health interventions and higher quality of care for the patients 
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involved. These benefits would have an immediate impact on antiretroviral programs, 
but could also be extended to other areas of primary care in developing countries. 
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The Spread ofHIV in Sub-Saharan Africa 
One of the largest public health threats facing the world today is the worldwide 
spread of the human immunodeficiency virus (HIV). Between 1990 and 2003 the 
prevalence ofHIV on a global scale has been steadily increasing (figure 1). This is a 
direct reflection of the spread of the virus in sub-Saharan Africa, which shows a similar 
trend, albeit on a much larger scale (figure 2). As shown in figures I and 2, the average 
percentage of the adult population with HIV in sub-Saharan Africa was almost ten times 
higher than the average worldwide. As of 2005, an estimated 40 million people 
worldwide are infected with HIV, with approximately five million new infections in 2005 
alone (UN AIDS 2005). No region has been hit harder than sub-Saharan Africa, where it 
is estimated that approximately 26 million people are currently living with HIV and 3.2 
million were newly infected in 2005 (UN AIDS 2005). 
At the beginning of the epidemic in the early 1980's men were identified as the 
group that was predominantly infected. However, that paradigm has shifted and on a 
global scale women now carry a much larger burden. In Southern Africa it is estimated 
that HIV infected females outnumber males by as much as two to one in some age groups 
(UNAIDS 2004). HIV infections in pregnant women are 20% or higher in six southern 
African countries (UNAIDS 2005). This statistic is troubling as the infection can be 
passed from mother to child. Without intervention, the mother-to-child transmission 
(MTCT) rate can reach 30-40% with prolonged breastfeeding (WHO 2002) and MTCT is 
responsible for nearly 90% of all HIV infections in infants and children. 
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Figure 1: The number of people living with H!VandA1DSworldwide and percentage of the adult 
population with HIV between 1990 and 2003. 
Figure 2: The number of people living with HIV and AIDS in sub-Saharan Africa and the percentage of the 
adult population with HIV between 1985 and 2003. 
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The Impact ofHIV on Economic, Societal, and Health Systems 
The high prevalence of HIV is detrimentally affecting economic structures in sub-
Saharan Africa. Worldwide, the impact of HIV on adult mortality has been greatest in 
individuals in their twenties and thirties (Heuveline 2004). This age group predominates 
in the workforce of Southern Africa where labor-intensive agriculture is the largest 
industry (USAID 2002). As a result AIDS deaths lead directly to a decrease in the 
number of workers and thus, productivity. The high prevalence ofHIV among those in 
the workforce can have a severe impact in the ability of an organization or company to 
function efficiently and, on a large scale, can impact the economy of a country as a 
whole. Productivity is affected by not only workers who fall sick or die, but by workers 
who must take time off to care for sick family members or to attend a funeral. Illness and 
absenteeism affect all sectors of employment. Some companies estimate that AIDS-
related costs could reduce productivity and profits by as much as 8% annually (USAID 
2002). 
The impact that HIV/AIDS has had on societal and family structures contributes 
to the severity of this public health emergency. Many of the infected are yotmg adults in 
the prime of their reproductive years and those who die of the disease often leave young 
children behind. At the end of2003, 15 million children under the age of fifteen had 
been orphaned worldwide with 12 fillion of those children living in sub-Saharan Africa 
(Andrews 2006). It is projected that by 2010, 18 million children under the age of 
eighteen will be orphaned in Africa (Andrews 2006). Furthermore, even if the 
prevalence of HIV is decreased, the number of orphans will continue to grow or, at least, 
remain high due to the long lag time between HIV infection and death (Andrews 2006). 
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Children are often categorized as single orphans, having one parent who is 
deceased, or double orphans, having two deceased parents. Throughout the 1990's the 
number of double orphans in sub-Saharan Africa has been steadily increasing. Figure 3 
displays the number of estimated double orphans in five African countries in the years 
1995 and 2000. These double-orphans will often reside with another relative, such as a 
grandmother, but it is uncertain whether child fostering within the extended family will 
be able to meet the needs of increasing numbers of orphans in the future (Heuveline 
2004). 
Figure 3: Estimates of the number of double orphans between 1995 and 2000 in five 
African countries 
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The high number of orphans places a heavy financial burden on the households 
that take them in. Households with orphans are more likely to be poor due to fewer 
7 
income-earning individuals supporting an increased number of dependants. One study 
conducted in East Africa has shown that school emollment rates among orphans are 
significantly lower than those of non-orphans; Single orphans have lower emollment 
rates than non-orphans and double orphans have lower emollment rates than single 
orphans, as demonstrated by figure 4 (Bicego 2003). East African double orphans 
between the ages of 6 and 10 are only half as likely to be at their appropriate education 
level as non-orphans. Between ages 11 and 14 double-orphans are only two-thirds as 
likely as non-orphans to be at the appropriate education level. If this trend continues, it 
will be a great challenge for African societies to absorb such a high number of under-
educated children. 
Figure 4: Probability of being at the proper education level by age group and orphan 
status 
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The toll that the pandemic has taken on health systems in sub-Saharan Africa has . 
been devastating. As HIV I AIDS prevalence rises, so does the number of opportunistic 
infections requiring medical attention. In many countries in sub-Saharan Africa, AIDS 
patients occupy over half of the hospital beds (US AID 2002). Because so many of the 
infected are poor, this burden largely falls on public hospitals and clinics. In South 
Africa, the total admissions in medical wards and the total number of hospital beds 
remained stable between 1995 and 2000. However, the HIVIAIDS-related admissions in 
all categories increased by a factor of seven and, currently, 46% of patients admitted to 
South African hospitals are HIV positive (Marchal 2005). 
The increase in HIV I AIDS is particularly burdensome for the public health 
workforce. HIV positive patients are often admitted to clinics and hospitals with 
advanced illness. With limited treatment options this leads to an increase in inpatient 
deaths, which is illustrated by the higher case fatality rate among HIV infected patients. 
A 1992 study in the Uganda demonstrated a mortality rate of5.5% among HIV-negative 
patients as compared to a mortality rate of 17.4 among HIV infected patients (Colvin 
200 I). This is a contributing factor to decreased staff morale and burnout (Marchal 
2005). 
Furthermore, a significant number of health care workers are HIV positive 
themselves. It is estimated that 16% of the health care workforce in South Africa is HIV 
positive (Benetar 2004). In low income countries low-cost HIV services are often 
accessible only through govermnent clinics. This leaves public-sector health care 
workers with little, if any, access to confidential HIV services. A study conducted in one 
South African hospital found that health care workers were reluctant to get an HIV test or 
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tmdergo treatment because to do so would require that they disclose their status to a co-
worker (Uebel2004). For this reason, HIV programs for clinical staff must be developed 
that assure anonymity and confidentiality. The loss of health care workers due to HIV-
related illness or death has dire implications in a region that is currently facing a health 
workforce shortage. Figures released by the Minister of Health show 31,000 vacant 
nursing posts in South Africa alone in 2003 (Uebel2004). 
Availability of Treatment Options 
In developed countries, highly active antiretroviral therapy (HAART) has been 
available for years. Pharmaceutical companies have brought to market a wide array of 
antiretroviral medications designed to arrest the virus at different parts of the replication 
cycle. With proper triple-drug antiretroviral therapy, the life of an HIV -positive 
individual may be prolonged indefinitely. Unfortunately, this type of treatment is not 
readily available in the regions of the world where it is most needed. 
Sub-Saharan Africa provides the most striking example. Despite having the 
highest burden ofHIV worldwide, very few people who are HIV positive have access to 
triple-drug therapy. In these developing countries concerns regarding cost of 
medications, patient compliance to therapy, and supply logistics have, until recently, 
prevented the initiation of antiretroviral therapy (ART) on a large-scale basis. There is a 
large health disparity that arises due to the lack of provision of comprehensive HIV 
treatment in poor countries. Mortality rates for people living with HIV are inversely 
related to the availability of antiretroviral therapy. Due to a shortage of treatment 
programs, mortality rates ofHIV positive adults are up to 20 times higher in low and 
10 
middle-income countries as compared to those living in wealthy industrialized countries 
(UNAIDS 2004). 
In 2003, the World Health Organization (WHO) called for lmprecedented action 
to ensure that by the end of 2005 at least 3 million people in need of ART will have 
access to it (World Health Organization 2003). The "3 by 5" initiative was supported by 
international organizations and has led to an influx of resources into HIV treatment in 
developing countries. As an example, in 2003 George Bush announced the President's 
Emergency Plan for AIDS Relief (PEPF AR). This program dedicated $15 billion over 
five years to HIV/AIDS prevention and treatment program in fifteen COlmtries. Of the 
$15 billion, fifty-five percent will be spent on implementing antiretroviral therapy 
programs in developing countries (Office of the US Global AIDS Coordinator 2004). 
Ultimately, the 3 by 5 goal was not met, and only 1 million people were on therapy by 
June 2005 (WHO 2005). While significant progress has been made, the unmet need for 
ART is still extremely high in sub-Saharan Africa where only 11% of the 4.7 million 
people who needed therapy were under treatment by June of2005 (WHO 2005). 
Description of Problem: The Limited Availability of Laboratory Testing 
There are many challenges to be overcome when introducing life-long disease 
management and therapy into resource-limited areas. Initially, the costs of the 
medications themselves were seen as the prohibitive aspect oflarge-scale treatment 
programs. In 2000, the cost of medications to treat one person with a first-line 
antiretroviral regimen for one year was between $10,000 and $12,000 USD (UNAIDS 
2004). A number of factors came into play to reduce the price of antiviral medications. 
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The introduction of first -line generic regimens and differential pricing by pharmaceutical 
companies resulted in a decrease in cost. Furthermore, the Clinton Foundation worked 
with drug manufacturers in India and South Africa and negotiated further price reductions 
for poor countries (UN AIDS 2004). Today the cost of medications to treat one person 
with a first-line antiretroviral regimen may be as low as $132 USD under the pricing 
structure negotiated by the Clinton Foundation (Clinton HIV I AIDS Initiative 2005). Due 
to the dramatic reduction in price, the cost of antiretroviral medications is no longer the 
barrier to treatment that it once was. 
Even with a high level of funding, one of the most pressing problems is 
maintaining the laboratory infrastructure necessary to properly treat patients. There are a 
number of clinical laboratory tests that are used through the duration of antiretroviral 
therapy. During the course of infection, CD4+ T-lymphocytes are attacked and steadily 
depleted by the human immunodeficiency virus. For this reason, a CD4 count is a good 
indicator of disease progression and is used to diagnose AIDS in asymptomatic 
individuals. Average CD4 counts in healthy individuals can differ across populations. In 
Nigeria the average CD4 count among HIV-negative men and non-pregnant women is 
approximately 800 cells/J.Ll (Aina 2005). In asymptomatic and mildly symptomatic HIV+ 
patients, antiretroviral therapy is often initiated when the CD4 count drops below 200 
cells/J.Ll and 350 cells/~tl respectively (DHHS 2006). Other common laboratory tests 
include a complete blood count (CBC), blood chemistry panel and plasma HIV viral load. 
The purpose of these tests is to determine if the HIV infection is recent, screen for the 
presence of co-infections and assess overall health (DHHS 2006). 
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At a minimum, the capacity should exist to run a CD4 count, a CBC and a basic 
blood chemistry panel. Accurate measures of these parameters can only be reliably 
obtained using expensive automated equipment that requires climate-controlled facilities, 
uninterrupted electricity and a reliable supply of reagents that often require a cold chain 
for transport and storage. While reduced reagent prices have been negotiated, most of the 
infrastructure problems with reagent transport and storage have yet to be solved. 
Furthermore, maintaining frmctional machinery is difficult in countries that lack the 
capacity to service broken equipment (Nkengasong 2005). Many developing countries 
are also experiencing a shortage of skilled laboratory technicians who are able to properly 
operate laboratory equipment (Archibald 2001). 
Despite these problems, it is generally felt that a lack of laboratory infrastructure 
should not preclude the implementation of ART in resource-poor settings. Four 
approaches may be considered for improving patient care with minimal laboratory 
resources. These include less frequent monitoring, reduced reliance on resource-
intensive tests such as HIV RNA viral load, use of clinical rather than laboratory criteria 
for patient monitoring and use of low-cost and technically appropriate diagnostics 
(Nkengasong 2005). Various combinations of these approaches have been used to offer 
care in the absence of readily available diagnostic equipment. Some programs in 
developing countries have used a central reference laboratory to serve multiple clinics 
within a large geographic area. In areas without CD4 capacity, clinicians may rely on 
direct patient examination using clinical staging guidelines developed by the WHO to 
determine eligibility for ARV's. If available, a total lymphocyte count may be used in 
the determination as well (Florence 2004). The WHO has stated that they will work with 
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member countries and diagnostic manufacturers to scale up laboratory infrastructure at 
the country level (WHO 2003). Improved laboratory technologies are being developed 
that are better suited for use in developing countries, but the introduction of automated 
equipment at the level of district and community clinics is still a long way off. For this 
reason, there is an immediate need for alternative diagnostic measures to ensure that 
patients receive the best care possible in rural and resource-limited clinics. 
The Need to Monitor Hemoglobin Values of Patients on Antiretroviral Therapy 
One operational definition of anemia is a hemoglobin or hematocrit value that is 
lower than two standard deviations below the mean (Aird 2003). The normal range for 
hemoglobin and hematocrit varies according to factors such as age, sex, ethnicity, 
geographic location and altitude. Decreased hemoglobin leads to a reduced ability of the 
blood to carry oxygen and a variety of symptoms may result from this condition. 
Moderate anemias may be asymptomatic or mildly symptomatic with patients describing 
such conditions as headache, fatigue and lethargy while severe anemia may present with 
such symptoms as increased heart rate and hypotension (Bell2002). 
Anemia occurs frequently in patients with HIV infection. A retrospective study 
evaluating over 30,000 HIV+ patients in the United States found the 1-year incidence of 
anemia to be 37% among patients with at least one AIDS-defining illness, 12% among 
asymptomatic patients with a CD4 count less than 200 and 3% among patients without 
clinical or immunological AIDS (Street 2002). The presence of anemia in HIV positive 
women has been demonstrated to correlate with worsening disease indicators such as 
CD4 count, vira1load and clinical AIDS-defining illnesses. It has also been 
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demonstrated that anemia is independently associated with decreased survival in HIV 
positive women (Berhane 2004). 
As HIV replicates in the body, it undergoes frequent random mutations. As a 
result, resistance to a single antiviral drug can develop rapidly (Champoux 2004). For 
this reason, combination therapy is advised. It has been found that triple-drug therapy 
demonstrates potent and sustained antiviral activity while monotherapy and dual therapy 
does not (DHHS 2006). There are currently over twenty FDA approved antiviral 
medications. When selecting a drug regimen in any setting factors such as potency and 
side-effects must be considered, but when selecting medications for use in developing 
countries the decision will be based heavily on availability and cost (WHO 2003). 
The WHO recommends four first-line ARV combination regimens to be used in 
developing countries. Each regimen contains two nucleoside reverse transcriptase 
inhibitors (NRTis) and one non-nucleoside reverse transcriptase inhibitor (NNRTI). The 
regimens will typically utilize stavudine (d4T) or zidovudine (AZT), lamivudine (3TC), 
and either nevirapine (NVP) or efavirenz (EFV) to form the combinations listed in table 
I. 
Table 1: First-line ARV Regimens in Adults and Adolescents and Characteristics That Can Influence 
Choice 
ARVRegimen Major Potential Toxicities Laboratory Monitoring 
Requirements 
d4T/3TC/NVP d4T-related neuropathy, No 
pancreatitis and lipoatrophy 
NVP-related hepatotoxicity 
and severe rash 
AZT/3TC/NVP AZT -related GI intolerance, Yes 
anemia, and neutropenia 
NVP-related hepatotoxicity 
and severe rash 
d4T/3TC/EFV d4T-related neuropathy, No 
pancreatitis and lipoatrophy 
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EFV -related CNS toxicity 
and potential for 
teratogenicity 
AZT/3TC/EFV ZDV -related GI intolerance, Yes 
anemia, and neutropenia 
EFV-related CNS toxicity 
and potential for 
teratogenicity 
Source: WHO Treatment Gmdelmes 2003 
Two of these regimens utilize the drug zidovudine (AZT) as a component. As 
listed in Table 1, one of the possible side effects of AZT is severe and potentially life-
threatening anemia. AZT was the first antiretroviral drug with a proven benefit when 
used to treat HIV/AIDS. One of the earliest clinical trials was ended early due to a 
significant improvement and increased mortality in the group receiving AZT. However, 
this group also experienced decreased hemoglobin levels with 21% of participants 
requiring multiple red-cell transfusions while only 4% in the placebo arm required 
transfusions (Richman 1987). Additional studies showed that lower-doses of AZT were 
effective and less toxic (Marks and Gulick 2005) but could not eliminate the risk of 
anemia completely. AZT manufacturers warn that significant anemia has occurred with 
AZT therapy and strongly recommend frequent blood counts in those patients receiving 
the drug (GlaxoSmithKline 2006). 
As patients with HIV infection progress in their disease status, they are more 
likely to develop AZT-related anemia (Street 2002). One study conducted in South 
Africa found that 7% of individuals placed on AZT experienced a grade 3 or 4 
hemoglobin adverse event. They also found that a baseline hemoglobin value <1 0.5 was 
strongly associated with grade 3 or 4 anemia over follow up (OR 11.5 95%CI [5.7-23.2]) 
(Fielding eta!. 2005). Grade 3 anemia is considered serious or severe and is defined as a 
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hemoglobin value between 6.5 g/dL and 7.9 g/dL. Grade 4 anemia is considered life 
threatening and is defmed as a hemoglobin value less than 6.5 (Kirshner 2004). A patient 
who develops grade three or four anemia risks dying from the condition if it left 
undetected and untreated. For this reason, it is recommended that AZT be prescribed 
only in instances where the hemoglobin levels may be closely monitored. Often, the 
anemia can be reversed if detected early. If this occurs it is recommended that AZT 
treatment be stopped and another drug substituted (WHO 2003). Accurate hemoglobin 
monitoring is critical to ensure successful.outcomes of patients treated with AZT. 
If the capacity to monitor hemoglobin is not in place, one option may be to use 
only those regimens that do not include AZT. However, it is unlikely that this could be 
possible in all instances. The most commonly used alternative medication is stavudine 
(d4T), which may also cause serious side effects. d4T does not affect hemoglobin levels 
but has been demonstrated to cause peripheral neuropathy or pancreatitis that is severe 
enough to require termination of use. For patients in developing countries who cannot 
tolerate d4T, the only available and affordable alternative is often AZT. For this reason 
nearly all large-scale ARV treatment programs will have a percentage of their patients on 
an AZT -containing regimen by necessity and thus, will require the capacity to monitor 
hemoglobin levels. 
Of additional concern are programs that utilize short-course antiretroviral therapy 
for prevention of mother to child transmission (PMTCT). The standard of care in many 
developing countries is to treat women in labor with a single dose of nevirapine. Recent 
concerns about nevirapine resistance (Palmer 2006) have led to a movement to 
incorporate other medications into the PMTCT regimen, and AZT is one of the drugs 
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currently being researched. Pregnant HIV positive women are at increased risk for 
anemia (Dairo 2005) and the use of AZT without adequate hemoglobin monitoring could 
compound their risk of developing severe anemia. 
Methods for Monitoring Anemia in IDV Patients 
It can be difficult to reliably measure hemoglobin values in areas with limited 
resources. The only methods of hemoglobin measurement that have been proven to be 
consistently accurate are those that use automated equipment. In order to obtain a 
hemoglobin value using automated equipment, blood is drawn from the patient into a 
tube treated with an anti-coagulant. The blood is then fed into the machine that performs 
the analysis and reports the hemoglobin value. This type of equipment has been in 
widespread use in developed countries for years but, as previously mentioned, it is 
unlikely that many district and community clinics in developing countries will have the 
necessary infrastructure and resources to reliably operate such equipment. It may also be 
difficult for poor clinics to keep the needles and blood collection tubes required for 
specimen collection in stock. For these reasons it is not yet feasible to implement 
automated laboratory equipment in every clinical site in a developing country and low-
tech alternative methods of measuring or estimating hemoglobin are necessary. 
The World Health Organization has developed an alternative method for 
hemoglobin estimation in resource-limited settings. According to WHO guidelines, in 
primary health care centers where laboratory facilities are not available or in the absence 
of laboratory-based hematology, the WHO color scale can be used together with clinical 
signs to evaluate anemia (WHO 2003). The WHO color scale is a method for assessing 
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anemia that requires very minimal equipment. A finger stick is done and a drop of blood 
is placed on absorptive paper. The color of the blood is then visually compared to a set 
of six color squares each of which corresponds to a hemoglobin value starting at 4 g/dl 
and increasing at 2 g/dl increments to a maximum of 14 g/dl. The hemoglobin estimate is 
recorded based on the best color match (WHO 2003). 
The Hemoglobin Color Scale represents an ideal public health intervention for 
resource-limited settings. Unlike automated equipment, the color card requires no 
electricity or reagents to operate. Due to the fact that it is made of sturdy paper, it can be 
stored indefinitely at any temperature and does not require refrigeration. As an added 
benefit, only a small drop of blood is required. This blood can be collected by doing a 
finger stick on the patient rather than drawing blood from a vein. A finger stick requires 
only a sharp lancet to break the skin which is far less expensive than the equipment 
required to collect enough venous blood for an automated hemoglobin measurement. 
Furthermore, the cost of the color cards is extremely low and training required for use is 
minimal. Due to the minimal cost and ease of operation, the Hemoglobin Color Scale 
could easily be implemented into health programs at the community level. District and 
community health centers could store and use the cards regardless of available 
infrastructure and health workers administering home-based care could easily carry the 
cards to private residences. This would allow for the screening of large numbers of 
patients in any type of setting. In addition to use in HIV treatment programs, the HbCS 
could be used for other public health applications requiring screening oflarge numbers of 
patients such as antenatal clinics, under 5 pediatric clinics and blood transfusion services. 
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However, the benefits of using this method must be evaluated relative to its accuracy as a 
diagnostic test. 
It is important to recognize that despite the cost and logistical benefits, the 
Hemoglobin color scale would only be successful if it provided a clinically reliable 
estimate of hemoglobin. Development of the WHO Hemoglobin color scale (HbCS) 
began in 1995 and it was made available commercially in 2001. Despite the fact that it 
has been in widespread use for five years, little research has been done to determine how 
useful the HbCS is as a tool for detecting anemia in areas where there is little or no 
laboratory capacity (WHO 2004). To date, very few studies have been published on the 
efficacy and/or effectiveness of the HbCS. Most of these studies sought to determine 
sensitivity (the probability that anemia will be detected using the HbCS among patients 
who are anemic) and specificity (the probability that anemia will not be detected using 
the HbCS among patients who are not anemic). None of the studies assessed the impact 
of using the HbCS on clinical outcomes such as appropriate disease management or 
improvement in patient condition (WHO 2004). 
A review of the published literature found that sensitivity and specificity of the 
HbCS were heterogeneous across studies with sensitivities ranging from 0.23 - 1.0 and 
specificities ranging from 0.41 - 1.0 being reported (Critchley 2005). This implies that 
under some conditions the HbCS may only accurately diagnose anemia in approximately 
one out of five patients who present with the condition. Additionally, under certain 
conditions the HbCS may indicate anemia in two out of five patients who do not have the 
disease. This discrepancy is likely due to differences in study design and study 
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populations. It was found that laboratory based (efficacy) studies often yielded higher 
sensitivities and specificities than clinic based (effectiveness) studies. 
Studies designed to determine the accuracy of the HbCS often focused on use of 
the color scale to determine if a patient was anemic but most did not assess the ability of 
the color scale to properly detect the severity of anemia. These studies often used a 
cutoff of II g/dl or 12 g/dl to define anemia. In many clinical settings, the degree of 
anemia is relatively unimportant. For example, a pregnant woman would be given the 
same treatment (iron supplements) regardless of whether her hemoglobin was 10 g/dl or 8 
g/dl. In the circumstances in which color-card use is indicated, it is less important to 
obtain a precise measurement of hemoglobin than to establish what clinical action is 
required (Lewis eta!. 1998). 
However, when using hemoglobin to determine clinical care with regard to 
antiretroviral therapy, the degree of anemia is precisely the measure used to determine the 
course of action. Using the example of the government ART program in Lusaka, 
Zambia, a patient who begins taking a regiment that includes AZT is monitored closely 
for a drug-induced anemia. If the patient's hemoglobin drops 2 g/dl or more from the 
baseline value, it is assumed that drug-induced anemia is occurring and the AZT 
component of the regimen is terminated. In this instance the test's ability to accurately 
predict the severity of anemia becomes far more important. Additionally, research is 
required to assess performance of the HbCS when used on the same patient over a 
prolonged time period, as would be the case when monitoring a patient on AZT. All 
studies reviewed were based on the results of one test per patient and to date, no long-
term cohort studies have been done to assess HbCS performance over time. 
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There are other concerns that should be addressed when assessing the suitability 
of use of the HbCS in antiretroviral programs including variability between persons 
conducting the test. One study evaluated interobserver variability when using the HbCS. 
When readings were taken by two separate people on 334 blood samples it was found 
that 81% of the readings were in agreement to within ±2 g/dl and that 19% of the 
readings varied by more than 2 g/dl (van den Broek 1999). If a drop in hemoglobin of2 
g/dl is the criteria for terminating AZT, this result implies that 19% of patients could 
potentially have their drug regimens changed or maintained based on errors from 
interobserver variability alone. 
This type of error can have potentially serious consequences. If a patient were 
incorrectly identified as having a drug-induced anemia then the AZT component of the 
drug regimen would likely be change to d4T. This could become problematic if the 
patient were tolerating AZT well but then experienced side effects from the d4T. In this 
case other drug alternatives must be sought out which may be more expensive, less 
convenient or less effective. A more severe scenario could result if a patient who 
experienced a drug-induced anemia was misdiagnosed due to observer variability. An 
improper test could lead a clinician to falsely believe that the patient was tolerating AZT 
when, in reality, continuation of AZT could pose a serious threat to the health of the 
patient. For reasons such as this it is in the best interest of both clinician and patient to 
ensure an accurate test for anemia. 
To summarize, there are multiple aspects of the HbCS diagnostic that are of 
concern. The first is a lack of precise data on overall sensitivity and specificity regarding 
the detection of anemia. The second is the questionable ability of the test to accurately 
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determine the severity of anemia. Finally, there is the possibility of poor consistency 
among users. In conclusion, the available evidence suggests that the Hemoglobin Color 
Scale may not perform accurately enough to be used as a primary component of an 
antiretroviral therapy program. 
Purpose of this Analysis 
A review of the existing data and literature clearly indicates that automated 
methods of hemoglobin measurement are proven to be the most accurate, but are also the 
most difficult to implement in resource-limited settings. There is much available 
evidence to suggest that the Hemoglobin Color Scale provides a far more convenient and 
less expensive method for hemoglobin estimation, yet the accuracy and validity of this 
method remains in question. A good diagnostic test for anemia is still needed to ensure 
that patients in developing countries are protected from possible anemia-related side 
effects while also assuring that they receive an optimal drug regimen for treatment of 
HIV. For this reason, further investigation into available options is needed. 
The purpose of this analysis is to examine considerations that future studies must 
address in order to determine the most accurate and logistically feasible method of 
hemoglobin analysis in antiretroviral therapy programs in developing countries. This 
includes research on the accuracy of the hemoglobin color scale when applied to an HIV 
positive population enrolled in an antiretroviral therapy program. Prospective studies 
must also evaluate the impact that HbCS use would have on clinical treatment in such a 
program and should also address the search for alternative methods of hemoglobin 
estimation. An ideal alternative method would be more accurate than the Hemoglobin 
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Color Scale, yet less resource-intensive than automated hematology equipment. 
Supporting evidence for one such alternative, a manual hematocrit measurement, is 
presented here. 
While a hemoglobin value measures the amount of hemoglobin present in the 
blood (measured in grams per deciliter), a hematocrit value measures the proportion of 
whole blood that is occupied by red blood cells and is expressed as a percentage. In areas 
where automated hematology equipment cannot be maintained, it is possible that a 
hematocrit level could be a better indicator of anemia than a hemoglobin estimate derived 
using the hemoglobin color scale. There are some potential advantages to using a 
hematocrit over the HbCS in a clinical setting. The first is that the testing method 
provides a numerical value without relying on subjective observations. With the 
hemoglobin color-card, a drop of blood is placed on a test strip and visually compared to 
a range of colored circles (Figure 5). This method relies heavily on subjective decisions 
made by the user, and may be prone to a high level of observer error depending on the 
individual running the test. To run a manual hematocrit test, a small centrifuge is 
required. Blood is placed in a capillary tube and spun down. The tube is then placed 
against a scale (Figure 6) so that the level of red cells may be determined as a percentage 
of the total (red cells+ plasma). As a result, there is far less subjective interpretation of 
this test. The blood tube is on a numeric scale and the value can be read directly, thus 
minimizing observer variability. 
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Figure 6: Manual hematocrit scale- The capillary tube is positioned with the bottom of the column of 
blood at the "0 "percent line and the top of the plasma at the "I 00" percent line. The height of the red cell 
column indicates the percent cell volume (source: Reidinger 1998) 
"" 
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Figure 7: Representation of a capillary tube after it has been spun. The 
red layer corresponds to the red blood cells and the gray layer 
corresponds to the plasma (source: Clark 2002) 
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One immediate drawback is that the hematocrit method would require more 
resources than the Hemoglobin Color Scale. Electricity or battery power is needed to 
operate the centrifuge and small capillary tubes would be required for blood collection. 
This may be problematic in rural areas, but many urban clinics have sufficient electricity 
to nm a centrifuge. Even with these requirements, this technology is far less expensive 
and easier to maintain than automated hematology machines. The HbCS costs 
approximately $0.12 per test (WHO 2004). After purchase of the centrifuge, the 
hematocrit cost per test would be approximately $0.15. In comparison, the cost per test 
using an automated hemoglobin analyzer starts at approximately $0.75 (WHO 2004). In 
areas where installation and maintenance of automated hematology equipment is not 
feasible, it may be a relatively simple matter to install and maintain a small centrifuge for 
hematocrit determination. A summary of the costs and benefits of the three methods of 
anemia determination can be found in table 2. The limited information available on low-
tech anemia diagnostics highlights the need for future research on both existing and 
alternative methods. 
Table 2: A cost-benefit comparison of three methods to diagnose anemia 
Method Hemoglobin Measurement Hemoglobin Estimate Hematocrit 
(Automated Hematology (Hemoglobin Color Scale) Measurement 
Machine) 
Accuracy Most Accurate Accuracy tested in resource- Accuracy untested in 
limited settings but results resource-limited settings 
questionable 
Cost per test Statts at 0.75 USD 0.12 USD 0.15 USD 
Requires Yes No Yes 
Electricity 
Requires Yes No No 
Reaoents 
Feasibility in Low Higb Moderate 
resource- Higb infrastructure and No infrastructure Requires electricity but 
limited maintenance requirements are requirements, limited limited supplies 
settings often prohibitive supplies needed otherwise. Minimal 
Most feasible option maintenance 
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Preliminary Evidence for Further Hematocrit Studies 
In order to provide supporting evidence for further study into alternative methods 
of anemia diagnosis, a representative antiretroviral program in sub-Saharan Africa will be 
examined. The government program in Lusaka, Zambia provides an example of a 
location where the issues surrolmding large-scale antiretroviral therapy are currently 
being studied. Zambia is located in the central part of southern Africa and has been one 
of the colmtries hardest hit by HIV/AIDS. The country has a total population of 
approximately eleven million and between thirteen and twenty percent of all adults are 
infected with HIV (WHO n.d). In 2004 the Zambian government decided that 
antiretroviral medications would be provided free-of-charge in the public sector (WHO 
Summary Country Profile 2005). With over 10,000 patients currently on antiretroviral 
therapy (Stringer n.d. ), the program in Lusaka provides a good setting to conduct research 
regarding provision ofHIV care in developing countries. 
A secondary analysis of existing data for the Lusaka ARV program was carried 
out to derive preliminary information on whether a hematocrit level could provide a more 
accurate estimate of hemoglobin than the HbCS method. This will serve as a hypothesis 
generating observational study to direct further investigation into both the hematocrit and 
HbCS methods of anemia detection. Data was obtained from patients enrolled in the 
Lusaka Urban District antiretroviral program in Zambia. This program is administered 
through the Center for Infectious Disease Research in Zambia (CIDRZ), a collaborative 
effort between the Lusaka Urban District Health Management Board and the University 
of Alabama at Birmingham, to provide antiretroviral therapy and related services free of 
charge to HIV positive individuals. Patient data is continuously collected to monitor 
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clinical outcomes. For the purposes of this paper, complete blood count (CBC) results 
from 7332 patients were used with the permission of Dr. Jeffrey Stringer, CIDRZ 
Director and Dr. Stewart Reid, CIDRZ Medical Director. The University of Zambia 
Research Ethics Committee and the Institutional Review Board at the University of 
Alabama at Birmingham have approved use of this data for research purposes. Presented 
in this paper is a secondary analysis of existing data that has been stripped of all unique 
identifiers and thus is exempt from IRB review according to the University of North 
Carolina Institutional Review Board (Office of Human Research Ethics 2006). This data 
is referenced because it has been recently derived from a large study in a developing 
country and may be reviewed to support the need for further studies into anemia detection 
methods. 
The study population consists of patients who were emolled in the Lusaka ART 
program between May 2004 and April2005. All emolled patients are HIV posative and 
program data indicates that approximately 65% of those are women (Stringer n.d.). 
Specific demographic data for the 7332 samples analyzed is unavailable, as age and sex 
identifiers have been stripped from the data set. In order to be eligible for emollment, 
patients must undergo voluntary counseling and testing (VCT) for HIV. Individuals who 
test positive at a VCT center may be referred for emollment into to the antiretroviral 
therapy program. Upon emollment, an initial history and physical exam is completed and 
blood is drawn for CD4 and CBC testing. Hemoglobin values are included in the CBC 
and may be used to assess overall health as well as to determine if it would be appropriate 
to start a patient on an initial regimen that includes AZT. Baseline bloodwork is analyzed 
at the CIDRZ central laboratory at Kalingalinga clinic in Lusaka. 
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The CBC results include hemoglobin and hematocrit values and were obtained 
using a Sysmex XT2000i analyzer (Sysmex Corporation, Japan). The XT 2000i is an 
FDA approved hematology analyzer that uses a sodium Iaury! sulfate (SLS) reagent to 
measure hemoglobin. The gold standard for hemoglobin measurement uses cyanide 
reagents, which can pose a hazard in use and disposal. The SLS method of hemoglobin 
measurement provides an accurate measure of hemoglobin without the use of toxic 
reagents. For the purposes of this paper, hemoglobin values obtained from the XT 2000i 
will serve as the reference standard. Hematocrit values from the XT 2000i are 
determined directly by measuring red cell volume in relation to sample volume. When a 
CBC is run both hemoglobin and hematocrit are measured simultaneously and may then 
be compared. 
The technology necessary for obtaining manual hematocrit values could be 
implemented in resource-limited settings. However, no studies have been done 
determine whether this would be a reliable method on which to base care in developing 
countries. As previously mentioned, an ideal method of anemia detection would perform 
better than the Hemoglobin Color Scale, but require fewer resources than automated 
hematology equipment. 
It is difficult to analyze the existing hematocrit data in such a way that results 
could accurately be compared with published data on the Hemoglobin Color Scale. Most 
published literature contains only information on sensitivity and specificity of the HbCS. 
Due to differences in study design, in many cases valid comparisons carmot be made so a 
precise measure has not yet been determined. 
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In order to approximate Hemoglobin Color Scale performance, data was selected 
from two studies for comparison. Study I is an efficacy study conducted on laboratory 
specimens in four laboratories (Lewis eta! 1998). The laboratories were located in the 
UK, South Africa, Thailand and Switzerland and the study was designed to assess the 
ability of laboratory workers to obtain accurate results from the HbCS under direct 
supervision. The patient population and laboratory workers were not representative of 
those that would be found in developing countries. This study was selected because of 
the high level of training and supervision and provides information on how well the 
HbCS can perform under ideal circumstances. Study 2 is an effectiveness study 
conducted in Malawi (van den Broek 1999). The purpose of this study was to evaluate 
HbCS performance in a "real-life" setting where the tests were done by lmsupervised 
district health care workers in an antenatal clinic. This study provided a patient 
population and clinical setting that best approximated conditions in the government 
clinics in Lusaka. 
Raw data was presented in study I, but not study 2, so results from study I were 
recalculated to be comparable to the data from study 2. For example, in study I raw data 
was presented and broken down into the following hemoglobin categories: less than 4 
g/dl, 4 to <6, 6 to <8, 8 to< 10, 10 to< 12, and 12 <14. In study 2 the raw data was not 
presented but calculated values for Sensitivity, Specificity, Positive Predictive Value and 
Negative Predictive Value were presented according to the following hemoglobin 
categories: Hb less than 6 g/dl, < 8 g/dl, <I 0 g/dl and< II g/dl. The raw data from the 
first study was recalculated according to the hemoglobin categories presented in study 2. 
The values that were collected in both studies were Sensitivity, Specificity, Positive 
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Predictive Value (the percentage of people who test positive for anemia and actually are 
anemic), and Negative Predictive Value (the percentage of people who test negative for 
anemia and are actually not anemic). These values are presented in Table 3. Also 
presented in Table 3 is data calculated from the hemoglobin and hematocrit values 
collected in the Lusaka antiretroviral therapy program. The hematocrit values are 
expressed in different units than hemoglobin values (a percentage rather than g/dl) and 
this difference is reflected in the table. 
Table 3: Comparison of Anemia Detection Methods in Three Settings- Sensitivity, 
specificity, positive and negative predictive values (P PV,NPV) and likelihood ratio (LR) 
for diagnosing anemia at different cut off points of hemoglobin concentration 
Definition of Anemia 
hemoglobin concentration 
(g/dl) or hematocrit value (%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
As previously described, data on the performance of the hemoglobin color scale 
was inconsistent between the two studies and varied depending on study design and 
population. The HbCS performed better far better in Study 1 than Study 2. This is most 
likely a reflection of the fact that Study 1 is an efficacy study carried out under strict 
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laboratory conditions while Study 2 is an effectiveness study carried out in an 
unsupervised setting which more closely approximates the setting in which the scale 
would actually be used. In study 1 and study 2, sensitivity of the HbCS was comparable 
in the Hb<l 0 and Hb<8 subsets, but specificity was greatly reduced in study 2 indicating 
an increased number of false positives. At hemoglobin levels below 6 g/dl, the HbCS 
had a significantly decreased sensitivity in study 2, correctly identifying only 50% of 
patients with a hemoglobin level below 6 g/dl. The performance of the HbCS was also 
poor with regard to the reported Positive Predictive Value in Study 2. This indicated that 
there was a low probability that individuals who tested positive for anemia actually were 
anemic. 
The data from the hematocrit values demonstrates a relatively high level of 
specificity without a large decrease in sensitivity when compared to the data in study 2. 
The positive predictive values for the hematocrit method are far higher than those of 
Study 2 and are comparable with those reported in Study 1. 
A good diagnostic test would have high percentage values for sensitivity, 
specificity, PPV and NPV and a test that performed perfectly would have a value of 1.0 
for all four parameters. A test that does not perform well in all areas may still be of value 
depending on the clinical situation. In some instances, high sensitivity may be far more 
important than high specificity. A good example is the diagnosis and treatment of 
anemia in an antenatal clinic. Obviously high sensitivity is preferable, as it is important 
that women who are anemic receive iron supplements. However, a high level of 
specificity is less important because there is little risk associated with the intervention. In 
this case, administering iron supplements to a woman who was incorrectly diagnosed as 
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anemic is unlikely to be harmful. In this specific situation a test for anemia with high 
sensitivity but low specificity would be valuable. 
When administering antiretroviral therapy, the misdiagnosis of anemia carries 
higher risk. It is important to exercise caution when changing a patient's drug regimen. 
Unnecessarily switching a patient off of AZT carries some risks such as the chance that 
the patient will react adversely to the substitute medication and may increase the risk that 
the patient will develop a drug resistant viral strain. For these reasons, a high level of 
specificity is desirable to prevent unnecessary drug regimen changes. 
A high level of sensitivity is preferred in this situation because individuals with 
lower hemoglobin at the time that AZT is initiated are at higher risk of developing severe 
and possible life-threatening anemia (Fielding et al. 2005). If a person is incorrectly 
diagnosed as anemic initially, they will be started on a regimen that does not contain 
AZT. The alternate medication (normally d4T) is equally effective and the patient's 
outcome should not be adversely affected unless a side effect is experienced as a result of 
the D4T component of the regimen. However, if a person who is anemic is incorrectly 
diagnosed as having normal hemoglobin levels and started on AZT, a severe adverse 
event is more likely. 
There are several limitations to the existing data. To date, no studies have been 
done to assess the accuracy of the HbCS in a Zambian HIV positive population. 
Furthermore, no data exists on the impact that HbCS use could have on clinical 
outcomes. While information is presented on hematocrit values obtained by an 
automated analyzer, the manual hematocrit method remains untested in antiretroviral 
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clinics in developing countries. Manual hematocrit readings may vary significantly due 
to the difference in measurement methods and the increased potential for human-error. 
While it is not possible to determine the best method for anemia diagnosis based 
on existing data, the preliminary findings do support the need for further studies as the 
data on the hematocrit comparison indicates that hematocrit might be a more accurate 
predictor of anemia in clinical settings. These findings also provide some guidance as to 
what information is needed for these studies. As previously mentioned, future studies 
should take into account not only sensitivity and specificity, but also the ability of a test 
to diagnose severity of anemia and interobserver variability. 
Considerations for Future Studies 
The need for further research on the role of the HbCS in ART programs has been 
well documented (WHO 2004). The evidence presented in this paper lays the 
groundwork for a prospective cohort study to assess the performance of the Hemoglobin 
Color Scale and a manual hematocrit as a predictor of anemia. The considerations that 
must be addressed in future studies are presented here and the Lusaka antiretroviral 
therapy program is used as an example. 
One of the problems identified in current studies is that health care workers who 
performed the HbCS readings may not have been blinded to the reference standard value 
and/or the patient's condition. A health care worker with pre-existing knowledge of the 
patient's health status, previous laboratory tests or the value obtained by the reference test 
could be more likely to interpret the HbCS value as one that closely matches the known 
information. An appropriate study design would ensure that health care workers 
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conducting the HbCS and hematocrit readings are blinded to patient condition and the 
value obtained by the reference standard. 
Outline of a Potential Study Design 
One example of an appropriate site to carry out this study is Kalingalinga clinic in 
Lusaka. This clinic provides an ideal setting because it houses an ART clinic, a district 
laboratory as well as the central laboratory for the ART program. Figure 8 illustrates the 
relevant duties of health care workers in each facility. The personnel in each facility 
carry out specific tasks that do not overlap. This is important because the three facilities 
are a part of the same clinic and blood samples could be analyzed using the reference 
method as well as the experimental method within similar time frames. Furthermore, the 
personnel in each facility do not interact and would not have any knowledge of other 
examination or test results. This would help to ensure that anemia diagnostic methods 
are evaluated accurately and that results reflect test performance and not technician bias. 
Figure 8: Diagram of tasks carried out in each of three clinic facilities and the ability to carry out a study 
with appropriate blinding 
/ 
Blinded 
/ 
Kalingalinga Clinic 
Staffed by district nurses, physicians and 
clinical officers 
Patients are examined by clinicians with 
access to chart containing previous 
hemoglobin values 
Blood is drawn for laboratory testing 
Kalingalinga Central Laboratory 
Laboratory technicians employed by 
CIDRZ run tests specific to ART 
program. Reference hemoglobin values 
would be obtained here using the 
Sysmex analyzer 
-- Blinded 
Blinded 
Kalingalinga District Laboratory 
District laboratory technicians run 
diagnostic tests including HbCS 
hemoglobin estimations Manual 
hematocrit testing would be 
implemented here 
Patients would be included in the study upon enrollment in the ART program, and 
would be randomized to receive either a manual hematocrit or a hemoglobin estimate 
using the HbCS. Both tests will be run in the district laboratory and the possibility exists 
that they may be run by the same technician. Because the outcome of one test may affect 
the technician's interpretation of the other, no patient will have both experimental tests 
done. To maintain appropriate blinding, each patient will have only one test or the other. 
Blood would be taken from a venous sample collected in an EDTA tube for the 
experimental test as well as the reference test. The district laboratory personnel at 
Kalingalinga would perform the hematocrit or HbCS estimate before delivering the 
specimen to the reference laboratory for a complete hematology panel. The personnel at 
the district laboratory are not involved in clinical care and do not work in the reference 
laboratory. Therefore they would be blinded to the clinical presentation of the patients, 
any prior hematology values recorded in the patient chart, as well as the measured 
reference standard. The hemoglobin results determined using the Sysmex analyzer would 
provide the reference standard to compare both the HbCS values and the Hematocrit 
values. Figure 9 outlines the proposed study design. Data should be stratified according 
to drug regimen (with AZT, without AZT) since it is possible that AZT could affect 
anemia prevalence to an extent that reported test performance is also affected. 
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Figure 9: Diagram of proposed study design 
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-
Hemoglobin 
B c2 
Comparisons of interested will be based on the reference standard in each group. Group A will be 
compared to C1 and group B will be compared to C2 to determine the differences between the experimental 
diagnostic methods. 
Both experimental methods of anemia detection, the HbCS and the manual 
hematocrit, are subject to variations due to operator error. Studies should seek to 
determine the extent of both inter and intra-operator variability. Operator training 
methods should also be reported in detail to determine if variability is a reflection of the 
inherent properties of the test or operator training and supervision. 
In this type of study, data collection and reporting should serve two purposes. 
The first is to assess the performance of the two anemia diagnostic methods described in 
a specific setting. The second is to provide results in such a way that they can be easily 
compared to results from other studies on other test populations. Test performance will 
vary depending on factors such as anemia prevalence and clinical definition of anemia 
used. For this reason, parameters such as these must be recorded and clearly defined 
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when reporting data. Information on patient indicators such as age, sex and pregnancy 
status should also be collected as these characteristics can affect baseline hemoglobin 
levels and anemia prevalence. The clinical setting and medical interventions being 
performed should be clearly stated, especially with regard to the risks and benefits of 
improper and proper anemia diagnosis. 
Data should also be collected in such a way that the impact of the test on clinical 
care can be assessed. For example, if conducting the study through the Lusaka ART 
program, anemia would be defined as Hb value less than 10.0 g/dl. This cutoff has been 
chosen because previous studies have shown that AZT-induced anemia is more likely to 
occur in patients with a hemoglobin value of less than 10.5 g/dl (Fielding 2005) and 
patients with baseline Hb levels below this value are started on antiretroviral regimens 
that do not include AZT. Data should be analyzed to determine the number of true 
positives, false positives, true negatives and false negatives so that sensitivity, specificity, 
PPV and NPV can be reported. This will provide information on test performance, but 
more importantly it would assess whether reliance on the experimental test method would 
have resulted in appropriate clinical care. For example, a high sensitivity would indicate 
that a high percentage of patients with anemia would have been given the correct initial 
reg1men. 
Finally, it is important to keep in mind that both experimental methods are 
unproven with regard to their impact on clinical care. For ethical reasons, studies should 
be designed in such a way that actual clinical care is based on the reference hemoglobin 
values and not the experimental values, especially in settings where an incorrect 
intervention carries significant risks. This should not compromise the validity of the 
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studies, as it would still be possible to determine the number of patients who would have 
received improper care had the reference value not been available. 
While this paper attempts to address some of the concerns involved in further 
research, there are some issues that are not addressed here. Aspects of future studies not 
considered in this paper include cost and funding of this type of work, and the timing and 
duration of such a study. However, this design can be used to form the basis for a 
funding or feasibility study proposal. 
Conclusion 
The HIV I AIDS pandemic is a serious threat to public health, economic 
development and stable societal structures in sub-Saharan Africa. Life-long 
Antiretroviral therapy can prolong the lives of HIV positive individuals indefinitely. For 
this reason, efforts are underway to make antiretroviral therapy available on a large scale 
in the areas of sub-Saharan Africa that are the hardest hit. These areas tend to be poor 
making provision of resource-intensive interventions extremely challenging. 
In order to implement large-scale ART, reliable laboratory infrastructure should 
be in place. However, in facilities without continuous electricity, adequate storage areas 
for reagents or easily accessible locations for maintenance personnel, operation of high-
tech laboratory equipment may not be possible. For this reason, the World Health 
Organization has recommended alternative diagnostics that do not rely as heavily on 
strong laboratory infrastructure (WHO 2004). 
The hemoglobin color scale has been suggested as one such alternate diagnostic 
tool to detect anemia in patients on ART. However, data on its accuracy and suitability 
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for use in clinical care is extremely lacking. For this reason, we propose a study with two 
objectives. The first is to determine whether the hemoglobin color scale is an appropriate 
diagnostic in an antiretroviral therapy program. The second objective is to examine a 
manual hematocrit as a possible option and determine whether it performs better than the 
HbCS in a clinical setting. Preliminary data taken from the Lusaka government 
antiretroviral therapy program suggests that hematocrit may be a better predictor of 
anemia and supports the need for further study. 
This research has the potential to change the standard of care in antiretroviral 
therapy programs on a global scale. If a low-tech method for anemia detection were 
proven to be an appropriate diagnostic on which to base clinical care it would provide a 
technology that could be implemented with confidence in antiretroviral therapy programs 
worldwide. Ultimately, this could improve public health interventions by leading to 
easier expansion of antiretroviral therapy programs in resource-poor settings and 
providing a higher quality of care for patients currently under care for HIV I AIDS 
treatment. Improvements in both of these areas are important if large-scale treatment 
programs are to be effective. 
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Appendix I -Abbreviations 
AIDS 
ART 
ARV 
AZT 
CDC 
CIDRZ 
d4T 
HAART 
HbCS 
HIV 
MTCT 
NNRTI 
NRTI 
PMTCT 
US AID 
VCT 
WHO 
Acquired Immunodeficiency Syndrome 
Antiretroviral Therapy 
Antiretroviral 
Zidovudine 
Centers for Disease Control and Prevention 
Center for Infectious Disease Research in Zambia 
Stavudine 
Highly Active Antiretroviral Therapy 
Hemoglobin Color Scale 
Human Immunodeficiency Virus 
Mother to Child Transmission 
Non-nucleoside Reverse Transcriptase Inhibitor 
Nucleoside Reverse Transcriptase Inhibitor 
Prevention of Mother to Child Transmission 
United States Agency for International Development 
Voluntary Counseling and Testing 
World Health Organization 
41 
References 
Aina 0, Dadik J, Charurat M, Amangaman P, Gurumdi S, MangE, Guyit R, Lar N, 
Datong P, Daniyam C, Kanki P, Abimiku A. Reference Values of CD4 T Lymphocytes in 
Human Immunodeficiency Virus-Negative Adult Nigerians. Clinical and Diagnostic 
Laboratory Immunology. 2005;12(4):525-530 
Aird W. Anemia. In: Furie B, Cassileth P, Atkins M, Mayer R, eds. Clinical Hematology 
and Oncology. Philadelphia, Pennsylvania: Churchill Livingstone; 2003:232-240 
Andrews G, Skinner D, Zuma K. Epidemiology of health and vulnerability among 
children orphaned and made vulnerable by HIV I AIDS in sub-Saharan Africa. AIDS Care 
2006; 18(3):269-276 
Archibald L, Reller B. Clinical Microbiology in Developing Countries. Emerging 
Infectious Diseases. 2001;7(2):302-305 
Bell A. Anemias: RBC Morphology and Approach to Diagnosis. In: Rodak B. ed. 
Hematology Clinical Principles and Applications. 2nd Ed. Philadelphia, Pennsylvania: 
W.B. Satmders Company; 2002:199-210 
Benatar S. Health Care Reform and the Crisis ofHIV and AIDS in South Africa. The 
New England Journal of Medicine 2004;351(1):81-92 
Berhane K, Karim R, Cohen M, Masri-Lavine L, Young M, Anastos K, Augenbraun M, 
Watts DH, Levine A. Impact of Highly Active Antiretroviral Therapy on Anemia and 
Relationship Between Anemia and Survival in a Large Cohort of HIV-Infected Women. 
Journal of Acquired Immune Deficiency Syndromes. 2004;37(2):1245-1252 
Bicego G, Rutstein S, Johnson K. Dimensions of the emerging orphan crisis in sub-
Saharan Africa. Social Science and Medicine. 2003;56:1235-1247 
Champoux J, Drew WL. Retroviruses, Human Immunodeficiency Virus, and Acquired 
Immunodeficiency Syndrome. In: Ryan K, Ray CG, eds. Sherris Medical Microbiology: 
An Introduction to Infectious Diseases. 4th Ed. New York, NY: McGraw-Hill; 2004:601-
616 
Clark K, Hippe! T. Routine Testing in Hematology. In:Rodak B. ed. Hematology Clinical 
Principles and Applications. 2nd Ed. Philadelphia, Pennsylvania: W.B. Saunders 
Company; 2002:199-210 
Clinical Pathology Department, Faculty of Medicine, University of Indonesia, Jakarta, 
Indonesia, Hematology Department, International Buddhist University, Osaka, Japan. 
Clinton HIV/AIDS Initiative. Antiretroviral (ARV) Price List. Version 12; January 2005 
42 
Comparison ofhaemoglobinometry by WHO Haemoglobin Colour Scale and copper 
sulphate against haemoglobincyanide reference method. Clinical and Laboratory 
Haemotology 2004;26:253-258 
Colvin M, Dawood S, Kleinschmidt I, Mullick S, Lallo U. Prevalence ofHIV and HIV-
related diseases in the adult medical wards of a tertiary hospital in Durban, South Africa. 
International Journal ofSTD and AIDS 2001;12:386-389 
Critchley J, Bates I. Haemoglobin colour scale for anaemia diagnosis where there is no 
laboratory: a systematic review. International Journal of Epidemiology 2005;34: 1425-
1434 
Dairo MD, Lawoyin TO, Onadeko MO, Asekun-Olarinmoye EO, Adeniji AO. HIV as an 
additional risk factor for anaemia in pregnancy: evidence from primary care level in 
Ibadan, Southwestern Nigeria. African Journal of Medicine and Medical Sciences 
2005;34(3):275-279 
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the 
Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 4, 2006 
Drechsler H, Powderly W. Switching Effective Antiretroviral Therapy: A Review. Clin 
Infect Dis 2002;35(10):1219-30 
Fielding K, Charalambous S, Pemba L, eta!. Haemoglobin adverse events and changes 
in haemoglobin amongst adults on zidovudine-containing antiretroviral therapy in South 
Africa. Poster presented at International Aids Society Conference. Rio de Janeiro, Brazil. 
July 2005 
Florence E, Dreezen C, Schrooten W, Van Esbroeck M, Kestens L, Fransen K, De Roo 
A, Colebunders R. The role of non-viral load surrogate markers in HIV -positive patient 
monitoring during antiviral treatment. International Journal ofSTD and AIDS 2004; 
15:538-542 
GlaxoSmithKline. Retrovir® [prescribing information]. Research Triangle Park, NC: 
GlaxoSmithKline; 2006 
Heuveline P. Impact of the HIV epidemic on population and household structure: the 
dynamics and evidence to date. AIDS 2004; 18(suppl2):S45-S53 
KirshnerJ, Hatch M, Hennessey D, Fridman M, Tannous R. Anemia in Stage II and III 
Breast Cancer Patients Treated With Adjuvant Doxorubicin and Cyclophosphamide 
Chemotherapy. The Oncologist 2004 ;9:25-34 
Lara AM, Mundy C, Kandulu J, Chisuwo L, Bates I. Evaluation and costs of different 
haemoglobin methods for use in district hospitals in Malawi. Journal of Clinical 
Pathology 2005;58:56-60 
43 
Lewis SM, Stott GJ, Wynn KJ. An inexpensive and reliable new haemoglobin colour 
scale for assessing anaemia. Journal of Clinical Pathology 1998;51:21-24 
Marchal B, De Brouware V, Kegels G. HIV/AIDS and the health workforce crisis: What 
are the next steps? Tropical Medicine and International Health 2005;10(4):300-304 
Marks K, Gulick R. Progress in HIV Treatment. In: Butera S. ed. HIV Chemotherapy- A 
Critical Review. Norfolk, United Kingdom: Caister Academic Press; 2005:1-3 
Nkengasong J, Weidle P. Implementing Antiretroviral Thearapy in Developing 
Countries: Logistic Issues and Lessons Learned. In: Butera S. ed. HIV Chemotherapy- A 
Critical Review. Norfolk, United Kingdom: Caister Academic Press; 2005:137-158 
Office of Human Research Ethics. Institutional Review Board. Instructions for 
Determination Whether Research or Similar Activities Require IRB Approval. Version 7; 
March 7 2006. Online 
http://ohre. unc.edu/forms/initial/not_ human_ subjects _research_ determination.doc 
Office of the United States Global AIDS Coordinator. The President's Emergency Plan 
for AIDS Relief US. Five-Year Global HIVIAIDS Strategy 2004 
PalmerS, Boltz V, Martinson N, Maldarelli F, Gray G, Mcintyre J, Mellors J, Morris L, 
Coffin J. Persistence of nevirapine-resistant HIV -1 in women after single-dose nevirapine 
therapy for prevention of maternal-to-fetal HIV-1 transmission. Proceedings of the 
National Academy of Sciences 2006; 1 03(18):7094-7099 
Reidinger T, Rodak B. Quantitative Laboratory Evaluation of Erythrocytes. In: Stiene-
Martin A, Lotspeich-Steininger C, Koepke J. eds. Clinical Hematology-Principles, 
Procedures, Correlations. Philadelphia, Pennsylvania: Lippincott-Raven 
Publishers;l998:111-113 
Street A, Milliken S. Haematological manifestations ofHIV infection. In: Crowe S, Hoy 
J, Mills J, eds. Management of the HIV-Infected Patient. London, United Kingdom: 
Martin Dunitz Ltd; 2002:281-283 
Stringer JSA, Zulu I, Levy J, Stringer E, Mwango A, Chi B, Mtonga V, Reid S, Cantrell 
R, Bulterys M, Saag M, Mar link R, Mwinga A, Ellerbrock T, Sinkala M. Rapid Scale-Up 
of Antiretroviral Therapy at Primary Care Sites in Lusaka, Zambia: Feasibility and Early 
Outcomes 
Richman D, Fischl M, Grieco M, Gottlieb M, Volberding P, Laskin 0, Leedom J, 
Groopman J, Mildvan D, Hirsch M, et al. The toxicity of azidothymidine (AZT) in the 
treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-
controlled trial. The New England Journal of Medicine 1987;317( 4): 192-197 
44 
Uebel K, Friedland G, Pawinsky R, Holst H. HAART for hospital health care workers-
an innovative progrannne. South African Journal of Medicine 2004;94(6):423-427 
UNAIDS. 2004 Report on the global AIDS epidemic. UNAIDS/04/16E. 
Geneva:UNAIDS 2004 
UNAIDS. AIDS epidemic update. UNAIDS/05.19E. Geneva:UNAIDS, 2005 
USAID. How Does HIVIAIDS Affect African Businesses? Washington DC:USAID 
USAID Report to Congress. USAID 's Expanded Response to HIVIAIDS. June 2002 
Van den Broek NR, Ntonya C, Mhango E, White SA. Diagnosing anaemia in pregnancy 
in rural clinics: assessing the potential of the Haemoglobin Colour Scale. Bulletin of the 
World Health Organization 1999;77(1):15-21 
World Health Organization. Country information website-Zambia. Online 
http:/ /who.int/countries/zmb/en/ (no date) Accessed 23 May 2006 
World Health Organization. Summary country profile for HIVI AIDS treatment scale-up. 
Geneva: World Health Organization, June 2005 
World Health Organization. Haemoglobin Color Scale: operational research agenda and 
study design, WHO/EHT/04.15. Geneva: World Health Organization, 2004 
World Health Organization. Prevention of HIV in infants and young children; Review of 
evidence and WHO's activities. WHO.HIV/2002.08. Geneva: World Health 
Organization, 2002 
World Health Organization. Progress on Global Access to HIV Antiretroviral Therapy, 
An update on "3 by 5". Geneva: World Health Organization, 2005 
World Health Organization. Scaling up Antiretroviral Therapy in Resource-Limited 
Settings: Treatment Guidelines for A Public Health Approach 2003 Revision. Geneva: 
World Health Organization, 2003 
45 
